Literature DB >> 1874925

Gonadotropin-releasing hormone antagonist plus testosterone: a potential male contraceptive.

W J Bremner1, C J Bagatell, R A Steiner.   

Abstract

No effective hormonal contraceptive has yet been devised for men. Through their suppressive effect on gonadotropin secretion, GnRH antagonists inhibit both testosterone (T) production and spermatogenesis in animals. Long term administration of an antagonist alone would result in androgen deficiency; this would cause unacceptable physiological and behavioral sequellae in men. Therefore, androgen replacement must be included in any GnRH antagonist regimen used in human male contraception. We tested the hypothesis that the combination of a GnRH antagonist plus T would suppress spermatogenesis in the male primate to azoospermic levels while maintaining normal serum T levels. We examined the effects of the GnRH antagonist Deterelix [N-Ac-DNal(2)1-DpCl-Phe2-DTrp3-DhArg(Et2)6 -DAla10-GnRH], alone and with simultaneous T replacement, on sperm production and serum T levels in adult male monkeys (n = 22). After 12 weeks of daily sc antagonist injection, all animals that received antagonist alone (n = 5) and those that 750 micrograms/kg.day antagonist plus T (n = 5) were azoospermic. After 16 weeks, four of five animals that received 250 micrograms/kg.day antagonist plus T became azoospermic. Control animals (n = 7) received daily injections of vehicle; sperm counts increased somewhat during the study period in that group. Castrate range T levels were achieved in animals receiving antagonist alone. T levels in the groups that received T supplementation and in the control group were in the normal male range throughout the treatment period. Sperm counts returned to the pretreatment range in all animals during the recovery period. We conclude that the combination of a GnRH antagonist plus T can induce azoospermia reversibly in this nonhuman primates species, and that a similar combination may be an effective contraceptive regimen in men. The GnRH antagonist alone may be an effective treatment for androgen-dependent neoplasia.

Entities:  

Keywords:  Androgens; Animals, Laboratory; Biology; Body Weight--changes; Clinical Research; Contraception; Contraception Research; Contraceptive Agents; Contraceptive Agents, Male; Endocrine System; Examinations And Diagnoses; Family Planning; Genitalia; Genitalia, Male; Histology; Hormone Antagonists--administraction and dosage; Hormones; Laboratory Examinations And Diagnoses; Laboratory Procedures; Physiology; Research Methodology; Semen--analysis; Seminal Vesicles; Sperm Count; Testosterone--administraction and dosage; Testosterone--analysis; Urogenital System

Mesh:

Substances:

Year:  1991        PMID: 1874925     DOI: 10.1210/jcem-73-3-465

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

Review 1.  Endocrine control of spermatogenesis: Role of FSH and LH/ testosterone.

Authors:  Suresh Ramaswamy; Gerhard F Weinbauer
Journal:  Spermatogenesis       Date:  2015-01-26

Review 2.  Testosterone therapy in men: clinical and pharmacological perspectives.

Authors:  A Gambineri; R Pasquali
Journal:  J Endocrinol Invest       Date:  2000-03       Impact factor: 4.256

Review 3.  Current status of fertility control methods in India.

Authors:  R S Sharma; M Rajalakshmi; R S Sharma; D A Jeyaraj
Journal:  J Biosci       Date:  2001-11       Impact factor: 1.826

4.  Effects of pharmacologically induced Leydig cell testosterone production on intratesticular testosterone and spermatogenesis†.

Authors:  Jin-Yong Chung; Sean Brown; Haolin Chen; June Liu; Vassilios Papadopoulos; Barry Zirkin
Journal:  Biol Reprod       Date:  2020-02-14       Impact factor: 4.285

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.